The human immunodeficiency virus type 2 (HIV‐2) is responsible for 4.5% of AIDS cases in
Portugal. Six HIV‐2 subtypes have been described so far, subtype A being proposed as …

Human immunodeficiency virus type 1 (HIV-1) was discovered in the early 1980s when the
virus had already established a pandemic. For at least three decades the epidemic in the …

Viremia is significantly lower in HIV-2 than in HIV-1 infection, irrespective of disease stage.
Nevertheless, the comparable proviral DNA burdens observed for these two infections …

Objective To compare baseline susceptibility to protease inhibitors among HIV-1 isolates of
subtypes C, F, G and CRF02_AG, and to identify polymorphisms that determine the …

Background We evaluated the prevalence of transmitted drug resistance (TDR) to integrase
strand-transfer inhibitors (INSTIs) and nucleoside/nucleotide reverse transcriptase inhibitors (…

Background & Aims Direct-acting antiviral (DAA) regimens provide a cure in >95% of patients
with chronic HCV infection. However, in some patients in whom therapy fails, resistance-…

Introduction Kidney transplant patients (KT) are at high risk for severe COVID‐19 and
presented attenuated antibody responses to vaccination when compared to immunocompetent …

Objective: To investigate whether and how mutations at position 89 of HIV-1 protease were
associated with protease inhibitor (PI) failure, and what is the impact of the HIV-1 subtype. …

Background Integrase strand transfer inhibitor–based regimens are recommended for first-line
therapy in human immunodeficiency virus type 2 (HIV-2). Nonetheless, dolutegravir (DTG…

Studies analyzing the relationship between BK polyomavirus (BKV) or JC polyomavirus (JCV)
infection and kidney transplant (KT) long term clinical outcomes are scarce. Therefore, we …